Tagawa Tsutomu, Dharmarajan Sekhar, Hayama Makio, Ishiyama Takaaki, Suda Takashi, Itano Hideki, Patterson G Alexander
Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110-1013, USA.
Ann Thorac Surg. 2004 Dec;78(6):1932-9; discussion 1939. doi: 10.1016/j.athoracsur.2004.06.008.
Soluble type I interleukin-1 receptor is a competitive inhibitor of interleukin-1 and may reduce its proinflammatory actions. The objective of this experiment was to demonstrate that endobronchial gene transfer of soluble type I interleukin-1 receptor IgG to donor lung grafts reduces posttransplant ischemia-reperfusion injury.
All experiments utilized an orthotopic left lung isograft transplant model. Donors were divided into three groups (n = 6 each) for endobronchial transfection: group I received 2 x 10(7) plaque-forming units of adenovirus encoding soluble type I interleukin-1 receptor IgG; group II received 2 x 10(7) plaque-forming units of nonfunctional control adenovirus encoding beta-galactosidase; and group III received 0.1 mL of saline. Left lungs were harvested 24 hours after transfection and stored for 18 hours before transplantation. Graft function was assessed 24 hours after reperfusion using three measurements: isolated graft oxygenation, wet-to-dry lung weight ratio, and tissue myeloperoxidase activity. Transgene expression of soluble type I interleukin-1 receptor IgG was also evaluated using enzyme-linked immunosorbent assay and immunohistochemistry.
Isolated graft arterial oxygenation was significantly improved in group I compared with groups II and III (281.8 +/- 134.8 versus 115.7 +/- 121.5 and 88.0 +/- 58.9 mm Hg, p = 0.0197 and p = 0.0081, respectively). Myeloperoxidase activity was also significantly reduced in group I compared with groups II and III (0.083 +/- 0.044 versus 0.155 +/- 0.043 and 0.212 +/- 0.079 optical density units per minute per milligram protein, p = 0.0485 and p = 0.0016, respectively). Expression of soluble type I interleukin-1 receptor IgG was detected only in lungs from group I.
Endobronchial gene transfer of soluble type I interleukin-1 receptor IgG to donor lung grafts subjected to prolonged cold ischemia ameliorates ischemia-reperfusion injury by improving graft oxygenation and reducing lung edema and neutrophil sequestration.
可溶性I型白细胞介素-1受体是白细胞介素-1的竞争性抑制剂,可能会降低其促炎作用。本实验的目的是证明将可溶性I型白细胞介素-1受体IgG经支气管内基因转移至供体肺移植物可减轻移植后缺血再灌注损伤。
所有实验均采用原位左肺同种异体移植模型。将供体分为三组(每组n = 6)进行支气管内转染:第一组接受2×10⁷ 个编码可溶性I型白细胞介素-1受体IgG的腺病毒空斑形成单位;第二组接受2×10⁷ 个编码β-半乳糖苷酶的无功能对照腺病毒空斑形成单位;第三组接受0.1 mL生理盐水。转染后24小时摘取左肺,在移植前保存18小时。再灌注24小时后,通过三项指标评估移植物功能:离体移植物氧合、湿干肺重量比和组织髓过氧化物酶活性。还使用酶联免疫吸附测定和免疫组织化学评估可溶性I型白细胞介素-1受体IgG的转基因表达。
与第二组和第三组相比,第一组的离体移植物动脉氧合显著改善(分别为281.8±134.8与115.7±121.5和88.0±58.9 mmHg,p = 0.0197和p = 0.0081)。与第二组和第三组相比,第一组的髓过氧化物酶活性也显著降低(分别为0.083±0.044与0.155±0.043和0.212±0.079光密度单位每分钟每毫克蛋白质,p = 0.0485和p = 0.0016)。仅在第一组的肺中检测到可溶性I型白细胞介素-1受体IgG的表达。
将可溶性I型白细胞介素-1受体IgG经支气管内基因转移至经历长时间冷缺血的供体肺移植物,可通过改善移植物氧合、减轻肺水肿和中性粒细胞滞留来减轻缺血再灌注损伤。